2017
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
Dhruva SS, Huang C, Spatz ES, Coppi AC, Warner F, Li SX, Lin H, Xu X, Furberg CD, Davis BR, Pressel SL, Coifman RR, Krumholz HM. Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). Hypertension 2017, 70: 94-102. PMID: 28559399, DOI: 10.1161/hypertensionaha.117.09221.Peer-Reviewed Original ResearchConceptsAntihypertensive therapySystolic blood pressure responseAdverse cardiovascular eventsFavorable initial responseBlood pressure responseHigher hazard ratioCardiovascular eventsCardiovascular outcomesHazard ratioMultivariable adjustmentHeart failureAverage SBPRandomized trialsOdds ratioCardiovascular diseaseSBPStudy participantsRespondersMonthsPressure responseImmediate respondersALLHATEarly responseInitial responseSuperior discrimination
2001
Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure
Chen Y, Wang Y, Radford M, Krumholz H. Angiotensin-converting enzyme inhibitor dosages in elderly patients with heart failure. American Heart Journal 2001, 141: 410-417. PMID: 11231438, DOI: 10.1067/mhj.2001.113227.Peer-Reviewed Original ResearchConceptsACE inhibitorsHeart failureClinical trialsSystolic dysfunctionElderly patientsLow dosesConfirmed heart failureDosage of angiotensinRepresentative elderly cohortDose-response relationshipHospital dischargeClinical factorsGuideline recommendationsElderly cohortMedication dataMedical recordsAdministrative databasesConnecticut hospitalsPractice guidelinesEnzyme inhibitorsPatientsLower mortalityHigh dosesDosesMortality